Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

According to the results of a new study, a cannabidiol (CBD) hydrogel microneedle patch may offer significant therapeutic ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

KLA Corp. $750.74-13.54-1.77% ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint ...